Choice and design of adjuvants for parenteral and mucosal vaccines

Savelkoul, Huub F. J. and Ferro, Valerie A. and Strioga, Marius M. and Schjins, Virgil E. J. C. (2015) Choice and design of adjuvants for parenteral and mucosal vaccines. Vaccines, 3 (1). pp. 148-171. ISSN 2076-393X (https://doi.org/10.3390/vaccines3010148)

[thumbnail of Savelkoul-etal-Vaccines-2015-Choice-and-design-of-adjuvants-for-parental-and-mucosal]
Preview
 Text. Filename: Savelkoul_etal_Vaccines_2015_Choice_and_design_of_adjuvants_for_parental_and_mucosal.pdf
Final Published Version
License: Creative Commons Attribution 4.0 logo
Download (374kB)| Preview

Abstract

The existence of pathogens that escape recognition by specific vaccines, the need to improve existing vaccines and the increased availability of therapeutic (non-infectious disease) vaccines necessitate the rational development of novel vaccine concepts based on the induction of protective cell-mediated immune responses. For naive T-cell activation, several signals resulting from innate and adaptive interactions need to be integrated, and adjuvants may interfere with some or all of these signals. Adjuvants, for example, are used to promote the immunogenicity of antigens in vaccines, by inducing a pro-inflammatory environment that enables the recruitment and promotion of the infiltration of phagocytic cells, particularly antigen-presenting cells (APC), to the injection site. Adjuvants can enhance antigen presentation, induce cytokine expression, activate APC and modulate more downstream adaptive immune reactions (vaccine delivery systems, facilitating immune Signal 1). In addition, adjuvants can act as immunopotentiators (facilitating Signals 2 and 3) exhibiting immune stimulatory effects during antigen presentation by inducing the expression of co-stimulatory molecules on APC. Together, these signals determine the strength of activation of specific T-cells, thereby also influencing the quality of the downstream T helper cytokine profiles and the differentiation of antigen-specific T helper populations (Signal 3). New adjuvants should also target specific (innate) immune cells in order to facilitate proper activation of downstream adaptive immune responses and homing (Signal 4). It is desirable that these adjuvants should be able to exert such responses in the context of mucosal administered vaccines. This review focuses on the understanding of the potential working mechanisms of the most well-known classes of adjuvants to be used effectively in vaccines.

CORE (COnnecting REpositories)